期刊文献+

耐万古霉素肠球菌筛选培养基的临床应用评估 被引量:1

Application evaluation of media for selecting vancomycin-resistant Enterococcusisolates
原文传递
导出
摘要 目的比较ChromID VRE产色琼脂培养基和含万古霉素6μg/ml血琼脂培养基对耐万古霉素肠球菌(VRE)的筛选和鉴定作用。方法以VITEK-2Compact鉴定和PCR方法对耐药基因检测为金标准,自检验科菌库中传出已鉴定的VRE、万古霉素敏感肠球菌(VSE)各30株,MRSA、其他链球菌各20株,对两种培养基性能进行比较;同时采集临床患者便标本350份接种于两种培养基,进行VRE筛选。结果对已知的VRE和非VRE两种筛选培养基符合率均达到100.0%;对临床便标本进行VRE的筛选中,ChromID VRE产色琼脂培养基符合率为100.0%,含万古霉素6μg/ml血琼脂培养基筛选出1株假阳性菌株。结论 ChromID VRE产色琼脂培养基对VRE筛选和鉴定准确,可应用于临床;含万古霉素6μg/ml血琼脂培养基,更适合应用于基层医院进行大样本量筛查。 OBJECTIVE To evaluate ChromID VRE agar and blood medium(containing 6 μg/ml vancomycin) for detecting and identifying vancomycin-resistant Enterococci(VRE).METHODS Thirty VRE strains,30 VSE strains,20 MRSA strains and 20 other Streptococci strains were inoculated in these two mediums separately.Moreover,350 stool specimens were cultured with these two mediums to select VRE strains.The VITEK2 Compact and PCR were used as standard methods for detecting resistant genes.RESULTS The sensitivity and specicity of the two mediums were all 100% when they were used to test the determined strains.To the 350 stool samples,the sensitivity and specificity of ChromID VRE medium were still 100%,but there was one false positive VRE strain isolated by the blood medium containing 6μg/ml vancomycin.CONCLUSION The sensitivity and specificity of ChromID VRE agar are high,and it can be used in clinical samples,and the blood medium containing 6μg/ml vancomycin can be used for selecting VREs in primary hospitals.
机构地区 北京医院检验科
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2012年第6期1310-1312,共3页 Chinese Journal of Nosocomiology
关键词 耐万古霉素肠球菌 培养基 临床应用 Vancomycin-resistant Enterococcus Mediums Clinical application
  • 相关文献

参考文献6

  • 1Cetinkaya Y,Falk P,Mayhall CG.Vancomycin-resistant en-terococci[J].Clinical Microbiology Reviews,2000,13:686-707.
  • 2Zirakzadeh A,Patel R.Vancomycin-resistant enterococci:col-onization,infection,detection,and treatment[J].Mayo ClinProc,2006,81(4):529-536.
  • 3Weber SG,Huang SS,Oriola S,et al.Legislative man-datesfor use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant en-terococci:position statement from the Joint SHEA and APICTask Force[J].Am J Infect Control,2007,35(2):73-85.
  • 4Kallstrom G,Doern CD,Dunne WM,Jr.Evaluation of a Chro-mogenic Agar under Development To Screen for VRE Colonization[J].J Clin Micro,2010,48(3):999-1001.
  • 5Ledeboer NA,Tibbetts RJ,Dunne WM.A new chromogenicagar medium,chromID VRE,to screen for vancomycin-resist-ant Enterococcus faecium and Enterococcus faecalis[J].Di-agn Microbiol Infect Dis,2007,59(4):477-479.
  • 6Winn WC, Koneman EW. Streptococci, enterococci and the streptococcus-like bacteria. Koneman's color atlas and text book of diagnostic microbiology, 6th ed[M]. Lippincott Wil liams Wilkins, Philadelphia, PA, 2006 : 672-764.

同被引文献19

  • 1Gedik H,Simsek F,Kantürk A,et al.Vancomycin-resistant Enterococci colonization in patients with hematological malignancies:screening and its cost-effectiveness[J].Afr Health Sci,2014,14(4):899-905.
  • 2Singh LK,Maheshwari DK,Shukla S.Antibacterial effect of butyryl alkannin from Arnebia euchroma against vancomycinresistant pathogens of Enterococcus faecalis causing urinary tract infections[J].Nat Prod Res,2015,29(24):2299-2301.
  • 3Lyu SY,Liu YC,Chang CY,et al.Multiple complexes of long aliphatic N-acyltransferases lead to synthesis of 2,6-diacylated/2-acyl-substituted glycopeptide antibiotics,effectively killing vancomycin-resistant Enterococcus[J].J Am Chem Soc,2014,136(31):10989-10995.
  • 4Jovanovic M,Milosevic B,Tosic T,et al.Molecular typing,pathogenicity factor genes and antimicrobial susceptibility of vancomycin resistant Enterococciin Belgrade,Serbia[J].Acta Microbiol Immunol Hung,2015,62(2):147-160.
  • 5Correa AA,Pignatari AC,da Silveira M,et al.Small hospitals matter:insights from the emergence and spread of vancomycin-resistant Enterococci in 2public hospitals in inner Brazil[J].Diagn Microbiol Infect Dis,2015,82(3):227-233.
  • 6Yarlagadda V,Sarkar P,Manjunath GB,et al.Lipophilic vancomycin aglycon dimer with high activity against vancomycinresistant bacteria[J].Bioorg Med Chem Lett,2015,25(23):5477-5480.
  • 7Masila VM,Midiwo JO,Zhang J,et al.Anti-vancomycin-resistant Enterococcus faeciumand E.faecalis activities of(-)-gossypol and derivatives from Thespesia garckeana[J].Nat Prod Commun,2015,10(4):613-616.
  • 8Singh K,Kumar S,Shekhar S,et al.Synthesis and biological evaluation of novel peptide BF2as an antibacterial agent against clinical isolates of vancomycin-resistant Enterococci[J].J Med Chem,2014,57(21):8880-8885.
  • 9Munita JM,Murray BE,Arias CA.Daptomycin for the treatment of bacteraemia due to vancomycin-resistant Enterococci[J].Int J Antimicrob Agents,2014,44(5):387-395.
  • 10Hall Snyder A,Werth BJ,Barber KE,et al.Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant Enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model[J].J Antimicrob Chemother,2014,69(8):2148-2154.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部